Ranitidine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Hypersecretory conditions
Adult: Initially, 1 mg/kg/hr via infusion, may increase rate at increments of 0.5 mg/kg/hr after 4 hours, as necessary. Doses up to 2.5 mg/kg/hr and infusion rates up to 220 mg/hr may be given.

Intravenous
Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 50 mg via slow IV inj as priming dose, followed by 0.125-0.25 mg/kg/hr via continuous infusion. Substitute oral therapy as soon as possible.

Oral
NSAID-associated ulceration
Adult: 150 mg bid or 300 mg at bedtime for 8 weeks.

Oral
Dyspepsia
Adult: 150 mg bid for up to 6 weeks. For short-term symptomatic relief: 75 mg repeated up to Max 4 doses daily, as necessary. Treatment duration: Up to 2 weeks of continuous use at one time.

Oral
Gastro-oesophageal reflux disease
Adult: 150 mg bid or 300 mg at bedtime for up to 8 weeks or if necessary, up to 12 weeks. Alternatively, 75 mg daily, as needed, no additional dose within 24 hours. For erosive esophagitis: May increase usual dose to 150 mg 4 times daily for up to 12 weeks; maintenance: 150 mg bid.
Child: As tab or oral solution: 3-11 years 5-10 mg/kg daily as in 2 divided doses up to Max of 600 mg daily; ≥12 years Same as adult dose.

Oral
Duodenal ulcers associated with H. pylori infection
Adult: 300 mg at bedtime or 150 mg bid given with oral amoxicillin and metronidazole for 2 weeks. Continue therapy without antibiotics for another 2 weeks. For patient with history of recurrent ulcer and have responded to short-term therapy, reduce dose to 150 mg at bedtime.

Oral
Prophylaxis of gastrointestinal haemorrhage from stress ulceration
Adult: 150 mg bid as a substitute for IV inj once oral therapy is possible.

Oral
Prophylaxis of acid aspiration during general anaesthesia
Adult: 150 mg given 2 hours prior to induction of anaesthesia and, and preferably, a 150 mg dose on the previous evening. In obstetric patients, 150 mg may be given at the start of labour and may be repeated at 6-hour intervals, as necessary.

Oral
Benign gastric and duodenal ulceration
Adult: Initially, 150 mg bid or 300 mg at bedtime for at least 4 weeks. May increase dose up to 300 mg bid, as necessary. Maintenance: 150 mg daily at bedtime.
Child: As tab or oral solution: 3-11 years 4-8 mg/kg daily in 2 divided doses to a Max of 300 mg daily for 4 weeks or up to 8 weeks if needed; ≥12 years Same as adult dose.

Oral
Hypersecretory conditions
Adult: Initially, 150 mg bid or tid, may be increased if necessary, up to 6,000 mg daily.

Parenteral
Benign gastric and duodenal ulceration
Adult: Up to 50 mg via IM or IV inj over 2 minutes or 25 mg/hour via intermittent IV infusion. Dose may be repeated 6-8 hourly.
Child: 6 months-11 years Initially, 2 or 2.5 mg/kg (Max 50 mg) via slow IV inj over 2 minutes. Maintenance of pH>4: 1.5 mg/kg via intermittent infusion 6-8 hourly. Alternatively, 0.45 mg/kg as loading dose via slow IV inj over 2 minutes followed by 0.15 mg/kg/hr via continuous infusion.  ≥12 years Same as adult dose.

Parenteral
Prophylaxis of acid aspiration during general anaesthesia
Adult: 50 mg via IM or slow IV inj 45-60 minutes prior to induction of anaesthesia.
Renal Impairment
Oral:
CrCl (mL/min) Dosage
<50 150 mg at night for 4-8 weeks. For patient with inadequate response, may adjust dose to 150 mg bid and may reduce back to maintenance treatment of 150 mg at night.
Parenteral:
CrCl (mL/min)
Dosage
<50
May reduce dose to 25 mg. 
Cách dùng
May be taken with or without food.
Hướng dẫn pha thuốc
Intermittent bolus injection: Dilute 50 mg in 0.9% NaCl or other compatible IV solution to a max concentration of 2.5 mg/mL (20 mL). Intermittent IV infusion: Dilute 50 mg in dextrose 5% or other compatible IV solution to a max concentration of 0.5 mg/mL (100 mL).
Chống chỉ định
History of acute porphyria.
Thận trọng
Patient with chronic lung disease, diabetes, factors predisposing to cardiac rhythm disturbances. Immunocompromised or severely ill patient. Rule out gastric malignancy or possibility of malignancy prior to initiation of therapy. Renal and hepatic impairment. Children. Pregnancy and lactation.
Phản ứng phụ
Significant: Rarely, mental confusion, depression, hallucinations.
Blood and lymphatic system disorders: Rarely, agranulocytosis, aplastic anaemia, granulocytopenia, haemolytic anaemia, leucopenia, pancytopenia (sometimes with marrow hypoplasia or marrow aplasia), thrombocytopenia.
Cardiac disorders: Dyspnoea, rarely, asystole, atrioventricular block, bradycardia (rapid IV administration), tachycardia, ventricular premature contractions.
Eye disorders: Rarely, reversible blurred vision.
Gastrointestinal disorders: Abdominal pain, constipation, nausea, abdominal distress, diarrhoea, vomiting.
General disorders and admin site conditions: Rarely, malaise.
Hepatobiliary disorders: Rarely, pancreatitis, cholestatic hepatitis, hepatic failure, hepatitis, jaundice.
Immune system disorders: Hypersensitivity reactions (e.g. fever, rash, bronchospasm, eosinophilia), anaphylaxis, angioneurotic oedema). Rarely, erythema multiforme.
Infections and infestations: Pneumonia.
Injury, poisoning and procedural complications: Pain, burning sensation, pruritus at injection site (IV/IM inj).
Investigations: Reversible changes in LFTs, elevated plasma creatinine, increased serum prolactin.
Metabolism and nutrition disorders: Rarely, acute porphyria.
Musculoskeletal and connective tissue disorders: Rarely, arthralgia, myalgia.
Nervous system disorders: Headache (sometimes severe), rarely, involuntary motor activity, dizziness, drowsiness, vertigo, agitation.
Psychiatric disorders: Rarely, insomnia.
Renal and urinary disorders: Rarely, acute interstitial nephritis.
Reproductive system and breast disorders: Rarely, reversible impotence.
Skin and subcutaneous tissue disorders: Rash, rarely, alopecia.
Vascular disorders: Rarely, vasculitis.
IM/IV/Parenteral/PO: B
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, drowsiness or blurred vision, if affected, do not drive or operate machinery.
MonitoringParameters
Monitor liver and kidney (e.g. serum creatinine) functions, occult blood with gastrointestinal bleeding, and signs of confusion.
Quá liều
Symptoms: Transient adverse effects similar to those experienced with normal doses, additionally, abnormalities of gait and hypotension. Management: Symptomatic and supportive treatment with removal of unabsorbed drugs from the gastrointestinal tract.
Tương tác
Altered prothrombin time and increased serum concentration with coumarin anticoagulants (e.g. warfarin). May reduce the excretion and increase plasma concentrations of procainamide and N-acetylprocainamide (high dose ranitidine). May alter the absorption of pH-dependent drugs which may result in either an increase in absorption (e.g. triazolam, glipizide, midazolam) or decrease in absorption (e.g. atazanavir, gefitnib, ketoconazole, delaviridine). Decreased absorption with co-administration of high dose sucralfate.
Lab Interference
False-positive result for urine protein tests with Multistix.
Tác dụng
Description: Ranitidine competitively and reversibly inhibits histamine at H2-receptors of the gastric parietal cells thereby inhibiting gastric acid secretion, gastric volume and reducing hydrogen ion concentration.
Pharmacokinetics:
Absorption: 50% of the administered dose is absorbed from the gastrointestinal tract (oral); rapidly absorbed (IM). Time to peak plasma concentration: 2-3 hours (oral); within 15 minutes (IM). Bioavailability: Approx 50% (oral); 90-100% (IM).
Distribution: Minimally penetrates the blood-brain barrier, crosses placenta and enters breast milk. Volume of distribution: Approx: 1.4 L/kg. Plasma protein binding: Approx 15%.
Metabolism: Metabolised in the liver to N-oxide (principal metabolite), S-oxide, and N-desmethyl metabolites.
Excretion: Mainly via urine (oral: 30%; IV: 70% as unchanged drug), faeces (as metabolites). Elimination half-life: 2.5-3 hours (oral); 2-2.5 hours (IV).
Đặc tính

Chemical Structure Image
Ranitidine

Source: National Center for Biotechnology Information. PubChem Database. Ranitidine, CID=3001055, https://pubchem.ncbi.nlm.nih.gov/compound/Ranitidine (accessed on Jan. 31, 2020)

Bảo quản
Store below 25°C. Protect from light and moisture.
Phân loại ATC
A02BA02 - ranitidine ; Belongs to the class of H2-receptor antagonists. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
References
Anon. Ranitidine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 13/06/2019.

Buckingham R (ed). Ranitidine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 13/06/2019.

Ranitidine Solution for Injection (Liva Pharmaceuticals Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 13/06/2019.

Ranitidine Syrup/Oral Solution (Aurobindo Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 13/06/2019.

Ranitidine Tablet (Vivimed Labs Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 13/06/2019.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ranitidine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2021 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
XEM THÊM
LESS
  • Axotac
  • Beemenocin
  • Cinitidine
  • Curan
  • Dapidong-150
  • Dudine
  • Emodum
  • Euphoric ACT-RIC
  • Gadean
  • Hanall Ranitidine HCl
  • Hazitac/Ranihasan/Haratac
  • Histac
  • Huonsdin
  • Ikorin
  • Intas Ranloc
  • Kantacid
  • LykaLydin 150/300
  • Moktin
  • Oferdin
  • Ponaltin
  • Prijotac
  • Proratine
  • Ranipin
  • Raniprotect
  • Ranison
  • Ranistin
  • Ranitan
  • Ranitidin DOMESCO
  • Ranitidin Meyer-BPC
  • Ranitidin NIC
  • Ranitidin Stada Pymepharco
  • Ranitidin Syncom
  • Ranitidin Vidipha
  • Ranitidine Flamingo
  • Ranitidine GSK
  • Ranitidine Torrent
  • Ranocer
  • Rantac
  • Rantac Inj
  • Ratidin
  • Ratidin F
  • Rintin-300
  • R-Loc
  • Ulcinorm
  • Umetac-150
  • Umetac-300
  • Uphatac
  • Zoran
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in